Literature DB >> 10637782

[Reproductive and developmental toxicity study of gadobenate dimeglumine formulation (E7155) (3)--Study of embryo-fetal toxicity in rabbits by intravenous administration].

Y Okuda1, F Sagami, P Tirone, A Morisetti, S Bussi, R E Masters.   

Abstract

Gadobenate dimeglumine formulation (E7155) was daily administered by intravenous injection at 0.3, 0.9 or 2.0 mmol/kg/day to mated NZW female rabbits (20/group) to assess the effect on embryo-fetal development. Treatment with 2.0 mmol/kg/day caused initial, notable loss of body weight and reduction in food consumption. Slightly reduced body weight gain and food intake were recorded at 0.9 mmol/kg/day. There were no obvious adverse effects in dams given E7155 at 0.3 mmol/kg/day. There was a slightly higher incidence of early intrauterine deaths at 0.9 and 2.0 mmol/kg/day. Morphological examination of fetuses at 2.0 mmol/kg/day revealed small eye/microphthalmia and/or retinal irregularities in three fetuses from three separate litters. There was also an increase in the incidence of additional and/or fused sternebral centres and 20-thoracolumbar vertebrae at this dosage. From these results, the No Observed Adverse Effect Level (NOAEL) for general toxicity of dams and embryo-fetal development was 0.3 mmol/kg/day.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10637782     DOI: 10.2131/jts.24.supplementi_79

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  17 in total

Review 1.  MRI evaluation and safety in the developing brain.

Authors:  Shannon Tocchio; Beth Kline-Fath; Emanuel Kanal; Vincent J Schmithorst; Ashok Panigrahy
Journal:  Semin Perinatol       Date:  2015-03-03       Impact factor: 3.300

Review 2.  The Management of Lymphoma in the Setting of Pregnancy.

Authors:  Chelsea C Pinnix; Therese Y Andraos; Sarah Milgrom; Michelle A Fanale
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 3.  Contrast-enhanced pulmonary MRA for the primary diagnosis of pulmonary embolism: current state of the art and future directions.

Authors:  Donald G Benson; Mark L Schiebler; Michael D Repplinger; Christopher J François; Thomas M Grist; Scott B Reeder; Scott K Nagle
Journal:  Br J Radiol       Date:  2017-04-12       Impact factor: 3.039

Review 4.  Imaging of Cardiovascular Disease in Pregnancy and the Peripartum Period.

Authors:  Theodore Pierce; Meline Hovnanian; Sandeep Hedgire; Brian Ghoshhajra
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-11-14

5.  Comparison of gadobenate dimeglumine and gadopentetate dimeglumine: a study of MR imaging and inductively coupled plasma atomic emission spectroscopy in rat brain tumors.

Authors:  Tian Zhang; Akira Matsumura; Tetsuya Yamamoto; Fumiyo Yoshida; Tadao Nose; Nobuhiro Shimojo
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

Review 6.  Fetal magnetic resonance imaging in obstetric practice.

Authors:  Aydın Köşüş; Nermin Köşüş; Betül Usluoğulları; Müzeyyen Duran; Nilgün Öztürk Turhan; Mehmet Tekşam
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

7.  Pregnancy and glial brain tumors.

Authors:  Shlomit Yust-Katz; John F de Groot; Diane Liu; Jimin Wu; Ying Yuan; Mark D Anderson; Charles A Conrad; Andrea Milbourne; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2014-03-09       Impact factor: 12.300

8.  Gadolinium Chelate Safety in Pregnancy: Barely Detectable Gadolinium Levels in the Juvenile Nonhuman Primate after in Utero Exposure.

Authors:  Joao Prola-Netto; Mark Woods; Victoria H J Roberts; Elinor L Sullivan; Christina Ann Miller; Antonio E Frias; Karen Y Oh
Journal:  Radiology       Date:  2017-09-04       Impact factor: 11.105

Review 9.  Gadolinium-Based Contrast Agent-Related Toxicities.

Authors:  Luca Pasquini; Antonio Napolitano; Emiliano Visconti; Daniela Longo; Andrea Romano; Paolo Tomà; Maria Camilla Rossi Espagnet
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

10.  [Indications and contraindications for contrast-enhanced MRI and CT during pregnancy].

Authors:  H Junkermann
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.